What is Zacks Research’s Estimate for CORT Q3 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research boosted their Q3 2025 EPS estimates for shares of Corcept Therapeutics in a research note issued on Wednesday, January 29th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.42 for the quarter, up from their prior estimate of $0.41. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.47 EPS, FY2025 earnings at $1.52 EPS and Q4 2026 earnings at $0.73 EPS.

Several other equities analysts have also recently commented on the stock. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Corcept Therapeutics has a consensus rating of “Buy” and a consensus target price of $88.25.

Corcept Therapeutics Stock Down 4.3 %

Shares of NASDAQ CORT opened at $66.92 on Monday. The company has a 50 day simple moving average of $56.02 and a 200-day simple moving average of $47.10. The company has a market capitalization of $7.01 billion, a P/E ratio of 53.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $71.29.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently made changes to their positions in CORT. Capital Performance Advisors LLP acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at $25,000. Kestra Investment Management LLC acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at $27,000. Kathleen S. Wright Associates Inc. acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at $36,000. USA Financial Formulas acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at $54,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Corcept Therapeutics in the 4th quarter valued at $58,000. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $50.54, for a total transaction of $111,188.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the sale, the insider now owns 85,318 shares in the company, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,011 shares of company stock valued at $1,461,568. Corporate insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.